Dr. Faisal Khan
Co-founder & CEO, OncoHelix
Dr. Faisal M. Khan is an Associate Professor at the University of Calgary. In his clinical role, Dr. Khan works as Director of Hematology Translational Lab at the University of Calgary; as an Associate Clinical Director of Histocompatibility and Immunogenetic Lab (HIL), and as Scientific Lead of Molecular Pathology Program in Alberta Precision Labs.
Dr. Khan obtained his Ph.D. in Human Molecular Genetics in India in 2006. He completed his postdoctoral training and clinical fellowship at the University of Calgary. Dr. Khan is a certified Diplomat of the American Board of Histocompatibility and Immunogenetics (ABHI).
Dr. Khan has more than 21 years of experience in Transplant Immunology, Cancer Genomics, and Histocompatibility and Immunogenetics. Based on his research, Dr. Khan has published over 100 research articles in scientific journals like Science, Blood, Transplantation, and Blood Advances. His research has been recognized by several awards including the American Society of Hematology (ASH) Achievement Awards in 2013, 2015, and 2018; and the American Society for Histocompatibility and Immunogenetics (ASHI) Scholar/Most Clinically Relevant Study awards in 2014, 2019, and 2022.
Dr. Khan has led the development, validation, and implementation of several advanced clinical molecular diagnostic tests including next-generation sequencing-based comprehensive genomic profiling for myeloid malignancies (2017) and solid tumors (2019); Serum-based cytokine profiling, and (3) post-bone-marrow transplantation engraftment monitoring testing. Dr. Khan is co-founder and CEO of OncoHelix Inc. an organization that specializes in providing esoteric cancer genomic and immunology testing.
Dr. Faisal M. Khan is an Associate Professor at the University of Calgary. In his clinical role, Dr. Khan works as Director of Hematology Translational Lab at the University of Calgary; as an Associate Clinical Director of Histocompatibility and Immunogenetic Lab (HIL), and as Scientific Lead of Molecular Pathology Program in Alberta Precision Labs.
Dr. Khan obtained his Ph.D. in Human Molecular Genetics in India in 2006. He completed his postdoctoral training and clinical fellowship at the University of Calgary. Dr. Khan is a certified Diplomat of the American Board of Histocompatibility and Immunogenetics (ABHI).
Dr. Khan has more than 21 years of experience in Transplant Immunology, Cancer Genomics, and Histocompatibility and Immunogenetics. Based on his research, Dr. Khan has published over 100 research articles in scientific journals like Science, Blood, Transplantation, and Blood Advances. His research has been recognized by several awards including the American Society of Hematology (ASH) Achievement Awards in 2013, 2015, and 2018; and the American Society for Histocompatibility and Immunogenetics (ASHI) Scholar/Most Clinically Relevant Study awards in 2014, 2019, and 2022.
Dr. Khan has led the development, validation, and implementation of several advanced clinical molecular diagnostic tests including next-generation sequencing-based comprehensive genomic profiling for myeloid malignancies (2017) and solid tumors (2019); Serum-based cytokine profiling, and (3) post-bone-marrow transplantation engraftment monitoring testing. Dr. Khan is co-founder and CEO of OncoHelix Inc. an organization that specializes in providing esoteric cancer genomic and immunology testing.
